Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 10 selected

Guidance programme

Showing 1 to 25 of 69

TitleReference numberPublishedLast updated
Sebelipase alfa for treating Wolman diseaseHST30
Velmanase alfa for treating alpha-mannosidosisHST29
Birch bark extract for treating epidermolysis bullosaHST28
Afamelanotide for treating erythropoietic protoporphyriaHST27
Lumasiran for treating primary hyperoxaluria type 1HST25
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiencyHST26
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophyHST24
Onasemnogene abeparvovec for treating spinal muscular atrophyHST15
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Delirium: prevention, diagnosis and management in hospital and long-term careCG103
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and educationNG213
Advocacy services for adults with health and social care needsNG227
Self-harm: assessment, management and preventing recurrenceNG225
Cefiderocol for treating severe drug-resistant gram-negative bacterial infectionsAMR2
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infectionsAMR1
Setmelanotide for treating obesity caused by LEPR or POMC deficiencyHST21
Social, emotional and mental wellbeing in primary and secondary educationNG223
Reducing sexually transmitted infectionsNG221
Social work with adults experiencing complex needsNG216
Vaccine uptake in the general populationNG218
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and overHST20
Elosulfase alfa for treating mucopolysaccharidosis type 4AHST19
Atidarsagene autotemcel for treating metachromatic leukodystrophyHST18
Integrated health and social care for people experiencing homelessnessNG214

Results per page

  1. 10
  2. 25
  3. 50
  4. All